- Recruiting
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
Updated: Feb 4
(SUCCESSOR-1)
CC-92480 - Mezi - Mezigdomide - CELMoD
NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1)
NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1)
The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Sponsor
ClinicalTrials.gov Identifier: NCT05519085
Official Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
First Posted : August 29, 2022
Click here for details on ClinicalTrials.gov
cereblon E3 ubiquitin ligase modulating agent CC-92480
Mezigdomide (Code C146660)
CC 92480
CC-92480
CELMoD CC-92480
Cereblon E3 Ligase Modulation Drug CC-92480
Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480
Cereblon Modulator CC-92480
Mezigdomide
MEZIGDOMIDE
Drug: CC-92480
Drug: Pomalidomide
Drug: Bortezomib
Drug: Dexamethasone
Locations
United States, Arizona
United States, Arkansas
United States, Connecticut
United States, Georgia
United States, Louisiana
United States, Mississippi
United States, New York
United States, Washington
Argentina
Austria
Canada, Quebec
Europe
Asia
China, Beijing
China, Fujian
China, Guangxi
China, Jiangsu
France
Germany
Ireland
Korea, Republic of
Poland
Spain
Turkey
RELATED POSTS
NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
